What is the recommended treatment for a 9 × 8 cm adrenal neuroblastoma?

Treatment of 9 × 8 cm Adrenal Neuroblastoma

A 9 × 8 cm adrenal neuroblastoma requires multimodal therapy consisting of induction chemotherapy (5-6 cycles), followed by surgical resection aiming for >90% tumor removal, then consolidation with tandem high-dose chemotherapy with autologous stem cell rescue, radiotherapy to the primary site, and postconsolidation immunotherapy with anti-GD2 antibody. 1

Risk Stratification First

This tumor size (9 × 8 cm) indicates high-risk disease requiring complete staging workup including:

• Bone marrow biopsy
• MIBG scan (or FDG-PET if MIBG unavailable)
• MYCN amplification status
• Histopathology grading
• Patient age
• Metastatic disease evaluation

The treatment algorithm depends critically on these factors, but tumor size alone suggests high-risk classification 2.

Phase 1: Induction Chemotherapy (First-Line)

Begin with 5 cycles of chemotherapy using either the ANBL12P1 or ANBL1531 regimen (preferred), or 6 cycles of ANBL0532 regimen. 1 These platinum- and alkylator-intensive regimens achieve approximately 80% partial response or better rates.

Key points about induction:

• The first 2 cycles typically use topotecan and cyclophosphamide
• Surgery is NOT performed upfront due to tumor size and likely vascular involvement
• Autologous peripheral blood stem cells are collected during this phase for later transplant
• Reassess disease after every 2 cycles to evaluate response and surgical feasibility

Phase 2: Surgical Resection

After chemotherapy-induced tumor shrinkage, perform surgical resection targeting >90% tumor removal (gross total resection), NOT complete resection with negative margins. 1, 3

Critical surgical considerations:

• Timing: After several cycles of cytoreductive chemotherapy when tumor becomes more resectable
• Goal: Remove >90% of tumor mass, which correlates with improved event-free survival and lower local relapse rates
• Do NOT sacrifice vital organs, major nerves, or major blood vessels to achieve complete resection—subtotal resection is preferred over morbid complications 1
• Image-Defined Risk Factors (IDRFs) guide surgical planning by defining tumor relationship to vascular structures 3

For this 9 × 8 cm tumor, open surgery is likely required. Minimally invasive approaches are only appropriate for tumors <6 cm after chemotherapy response 4.

Phase 3: End-Induction Assessment

Perform complete disease reassessment after induction to determine consolidation eligibility:

• Partial response or better → proceed to consolidation
• Minor response/stable disease → consider bridging therapy, then consolidation if response achieved 1
• Progressive disease → alternative therapy protocols

This assessment is critical: patients with partial response or better who proceed to consolidation have significantly improved outcomes 1.

Phase 4: Consolidation Therapy

Administer tandem transplantation with 2 consecutive rounds of high-dose chemotherapy with autologous stem cell rescue (Category 1 recommendation). 1

The regimen consists of:

1. First transplant: Thiotepa/cyclophosphamide
2. Second transplant (6-10 weeks later): Dose-reduced carboplatin/etoposide/melphalan (CEM)

This tandem approach provides superior 3-year event-free survival (61.6% vs 48.4% for single transplant) based on the COG ANBL0532 randomized phase 3 trial 1.

Plus: Consolidative radiotherapy to the primary tumor site and any residual metastatic disease sites identified at end-induction. 1

Exception for Single Transplant

Only two specific subgroups may receive single transplant instead of tandem:

1. Stage L2, ≥18 months, unfavorable histology, MYCN non-amplified
2. Stage M, 12-<18 months, MYCN non-amplified with other unfavorable features

These groups have 5-year EFS rates of 75-80%, justifying less intensive consolidation 1.

Phase 5: Postconsolidation Immunotherapy

Following consolidation, patients receive anti-GD2 monoclonal antibody-based immunotherapy, which has become standard in the modern treatment era 1.

Common Pitfalls to Avoid

1. Do NOT attempt upfront surgical resection of a 9 × 8 cm adrenal neuroblastoma—this increases surgical morbidity without improving outcomes 1

2. Do NOT pursue negative surgical margins at the expense of vital structures—the goal is >90% resection, not R0 resection 1

3. Do NOT skip tandem transplant for standard high-risk patients—single transplant is inferior except in the two specific favorable subgroups noted above 1

4. Do NOT delay consolidation for patients achieving partial response or better—proceeding to consolidation improves outcomes even with incomplete response 1

Prognosis Context

High-risk neuroblastoma has an estimated 5-year event-free survival of 51% with modern multimodal therapy 1. The 9 × 8 cm size indicates substantial disease burden, making adherence to this complete treatment algorithm essential for optimal outcomes.